Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $92 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.